Biotechnology

As iBio heads to a key investor conference, its AI-driven antibody platform aims to solve the GLP-1 paradox: achieving sustainable weight loss by preserving muscle.

A biotech startup is targeting a hidden cause of chemo resistance. An AI firm claims it can predict a drug's success. Their deal is a major market signal.

With new data on its recently approved therapy TREGZI™, Orca Bio aims to shift the goal of cancer transplants from mere survival to a life free of complications.

As RNA drugs boom, a critical bottleneck emerges: quality control. A San Diego firm's new tool promises to deliver a complete picture, speeding up development.

PeptidePrices' new market intelligence platform brings radical transparency to the chaotic online peptide market, centralizing data to empower researchers.

With Hepatitis C royalties declining, Enanta Pharmaceuticals faces investors this month to sell its vision: a future built on novel RSV and immunology drugs.

ElevateBio's new COO, Steven Falcone, is a strategic weapon against the crushing cost of advanced therapy manufacturing. This isn't just a hire; it's a war on the price of miracles.

Adicet Bio nears a pivotal data readout for its lupus CAR-T, now viable for outpatient use, while launching a novel solid tumor attack in prostate cancer.

UCB's landmark agreement with the U.S. government trades pricing concessions for tariff exemptions, signaling a major shift in industry strategy.

As it launches a pivotal trial for its MYC inhibitor, Persevere Therapeutics adds a seasoned CEO to its board, signaling a sharp focus on funding and strategy.

A strategic merger combines Chemomab's promising drug, nebokitug, with Scipher's AI platform, aiming to de-risk development and transform RA treatment.

With its new COVID vaccine approved, Novavax is leveraging global partners like Sanofi to earn royalties, proving an asset-light model can rival industry giants.

BioLineRx secures crucial funds for its cancer drugs, but at a cost. We dissect the deal, the shareholder dilution, and what it reveals about biotech financing.

After a strategic reset, Australian biopharma Immuron reports record sales and a stronger cash position, pivoting to partner its high-value drug candidates.

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

As a deadly Bundibugyo ebolavirus outbreak grips the DRC, a $16.5M CEPI investment in Egypt's Minapharm marks a pivotal shift toward African health sovereignty.

An Argentine firm is scaling up to challenge global pharma giants, promising a more stable supply of a critical drug and a new model for trust in medicine.

With zero recurrences in a pivotal trial, a novel immunotherapy combination is rewriting the rules for early-stage colon cancer, targeting tumors once thought untouchable.